Gyeonggi-do, South Korea

Joo Han Lee

This inventor holds 4 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Boryung Pharmaceutical Co., Ltd., Raphas Co., Ltd., Other. Active years: 2002-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joo Han Lee. Retrieved from https://idiyas.com/inventor/joo-han-lee-4ujqhktd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 4 

% Patents Active = 75.0



Average Co-Inventor Count = 7.8

ph-index = 1

Forward Citations = 12(Granted Patents)


Location History:

  • Seo-ku, Taejun, KR (2002)
  • Seoul, KR (2014 - 2016)
  • Gyeonggi-do, KR (2023)

Company Filing History:


Years Active: 2002-2023

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Joo Han Lee: Innovator in Microneedle Technology

Introduction

Joo Han Lee is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceutical technology, particularly in the development of innovative drug delivery systems. With a total of four patents to his name, Lee's work focuses on enhancing the efficacy and safety of medical treatments.

Latest Patents

One of Lee's latest patents is a microneedle percutaneous patch containing donepezil. This invention relates to a composition for preparing a microneedle, a soluble microneedle, and a microneedle percutaneous patch comprising the soluble microneedle. The soluble microneedle has a high drug loading capacity and excellent strength, allowing it to contain an effective amount of donepezil or a pharmaceutically acceptable salt thereof, even with a small area of the microneedle. This innovation is economical and produces a lower level of skin irritation, making it a valuable advancement in drug delivery.

Another notable patent is for a compound having angiogenesis inhibitory activity, along with a method for preparing the compound and a pharmaceutical composition comprising it. This anti-angiogenic compound, represented by Chemical Formula I, potently suppresses angiogenesis and is applicable to the prevention and treatment of diseases caused by aberrant activity of vascular endothelial growth factor. This compound serves as an effective anti-angiogenic agent.

Career Highlights

Joo Han Lee has worked with Boryung Pharmaceutical Co., Ltd., where he has contributed to various innovative projects. His expertise in pharmaceutical technology has positioned him as a key player in the industry, driving advancements in drug delivery systems.

Collaborations

Lee has collaborated with notable coworkers, including Ji Han Kim and Je Hak Kim. Their combined efforts have led to significant developments in the field of pharmaceuticals.

Conclusion

Joo Han Lee's contributions to microneedle technology and anti-angiogenic compounds highlight his role as an influential inventor in the pharmaceutical industry. His innovative approaches continue to pave the way for advancements in drug delivery and treatment options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…